[1] Lazzarotto T, Blázquez-Gamero D, Delforge ML,et al. Congenital cytomegalovirus infection: A narrative review of the issues in screening and management from a panel of european experts[J].Front Pediatr,2020,8:13.
[2] Bristow BN, O'Keefe KA, Shafir SC, et al. Congenital cytomegalovirus mortality in the United States, 1990-2006[J].PLoS Negl Trop Dis,2011,5(4):e1140.
[3] Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection[J].Rev Med Virol,2007,17(4):253-276.
[4] Gantt S, Dionne F, Kozak FK, et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection[J].JAMA Pediatr,2016,170(12):1173-1180.
[5] Goderis J, De Leenheer E, Smets K, et al. Hearing loss and congenital CMV infection: a systematic review[J].Pediatrics,2014,134(3):972-982.
[6] Ronchi A, Zeray F,Lee LE,et al. Evaluation of clinically asymptomatic high risk infants with congenital cytomegalovirus infection[J].J Perinatol,2020, 40(10) :89-96.
[7] Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate:consensus recommendations for prevention, diagnosis, and therapy[J].Lancet Infect Dis,2017, 17(2):e177-188.
[8] Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection[J].Rev Med Virol,2007,17:355-363.
[9] Goderis J, De Leenheer E, Smets K, et al. Hearing loss and congenital CMV infection: a systematic review[J].Pediatr,2014,134(5):972-982.
[10] Stehel EK, Shoup AG, Owen KE, et al. Newborn hearing screening and detection of congenital cytomegalovirus infection[J].Pediatrics,2008,121(2):970-975.
[11] Manicklal S, Emery VC, Lazzarotto T, et al. The “silent”global burden of congenital cytomegalovirus[J].Clin Microbiol Rev,2013, 26(1):86-102.
[12] Johnson JM, Anderson BL. Cytomegalovirus: should we screen pregnant women for primary infection? [J].Am J Perinatol,2013, 30(1):121-124.
[13] Cahill AG, Odibo AO, Stamilio DM, et al. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis [J].Am J Obstet Gynecol,2009, 201:466.e1-7.
[14] Revello MG, Tibaldi C, Masuelli G, et al. Prevention of primary cytomegalovirus infection in pregnancy [J].EBio Medicine,2015, 2(9):1205-1210.
[15] Delforge ML, Costa E, Brancart F, et al.Presence of cytomegalovirus in urine and blood of pregnant women with primary infection might be associated with fetal infection [J].J Clin Virol,2017, 90(1):14-17.
[16] Enders M, Daiminger A, Exler S,et al. Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience [J].Prenat Diagn,2017, 37(2):389-398.
[17] Uematsu M, Haginoya K, Kikuchi A, et al. Asymptomatic congenital cytomegalovirus infection with neurological sequelae: are trospective study using umbilical cord [J].Brain Dev,2016, 38(3):819-826.
[18] Foulon I, De Brucker Y, Buyl R, et al. Hearing loss with congenital cytomegalovirus infection [J].Pediatrics,2019, 144:e20183095.
[19] Ross S, Long SS, Kimberlin DW. Closer to universal newborn screening for congenital cytomegalovirus infection but far away from antiviral therapy in all infected infants [J].J Pediatr,2018,199(1):7-9.
[20] Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate:consensus recommendations for prevention, diagnosis, and therapy [J].Lancet Infect Dis,2017,17(6):e177-e188.
[21] Leruez-Ville M, Magny JF, Couderc S, et al. Risk factors for congenital cytomegalovirus infection following primary and nonprimary maternal infection: a prospective neonatal screening study using polymerase chain reaction in saliva [J].Clin Infect Dis,2017,65(2):398-404.
[22] Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection [J].JAMA,2010 ,303(14):1375-1382.
[23] Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system:a randomized, controlled trial [J].J Pediatr,2003,143(1):16-25.
[24] Oliver SE, Cloud GA, Sánchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system [J].J ClinVirol,2009 ,46(Suppl 4):S22-S226.
[25] Kimberlin DW, Acosta EP, Sánchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease [J].J Infect Dis,2008, 197(6):836-845.
[26] Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease [J].N Engl J Med,2015, 372(10):933-943.
[27] Luck SE, Wieringa JW, Blázquez-Gamero D,et al. Congenital cytomegalovirus: a European expert consensus statement on diagnosis and management [J].Pediatr Infect Dis J,2017, 36(12):1205-1213. |
2021, Vol. 38 
